Overview
Qualitative or quantitative defects of collagen 6 encompass a spectrum of inherited muscle disorders caused by mutations in the genes encoding collagen VI (COL6A1, COL6A2, and COL6A3). Collagen VI is a major structural component of the extracellular matrix surrounding muscle fibers, tendons, skin, and other connective tissues. When collagen VI is either reduced in quantity (quantitative defect) or structurally abnormal (qualitative defect), it leads to a range of clinical conditions collectively known as collagen VI-related myopathies. The most recognized conditions within this spectrum include Ullrich congenital muscular dystrophy (UCMD) at the severe end, Bethlem myopathy at the milder end, and an intermediate phenotype bridging the two. The primary body systems affected are the musculoskeletal and connective tissue systems. Key clinical features include progressive muscle weakness, joint contractures (particularly of the elbows, ankles, and fingers), and proximal joint hyperlaxity (especially of the wrists and fingers), which is a distinctive hallmark. Patients may also experience skin abnormalities such as soft, velvety skin, keloidal scarring, and follicular hyperkeratosis. In more severe forms such as UCMD, respiratory insufficiency can develop early and may require ventilatory support. Bethlem myopathy typically presents with a milder, slowly progressive course, though contractures and mild respiratory compromise can still occur over time. Currently, there is no curative treatment for collagen VI-related myopathies. Management is supportive and multidisciplinary, focusing on physical therapy to maintain mobility and manage contractures, respiratory monitoring and intervention when needed, and orthopedic management. Research into potential therapies, including approaches to enhance collagen VI production or correct underlying defects through gene therapy, is ongoing but remains largely experimental.
Variable
Can be inherited in different ways depending on the underlying gene
Variable
Can begin at different ages, from infancy through adulthood
Treatments
No FDA-approved treatments are currently listed for Qualitative or quantitative defects of collagen 6.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Qualitative or quantitative defects of collagen 6 at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Qualitative or quantitative defects of collagen 6.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Qualitative or quantitative defects of collagen 6.
Community
No community posts yet. Be the first to share your experience with Qualitative or quantitative defects of collagen 6.
Start the conversation →Latest news about Qualitative or quantitative defects of collagen 6
No recent news articles for Qualitative or quantitative defects of collagen 6.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Qualitative or quantitative defects of collagen 6
What is Qualitative or quantitative defects of collagen 6?
Qualitative or quantitative defects of collagen 6 encompass a spectrum of inherited muscle disorders caused by mutations in the genes encoding collagen VI (COL6A1, COL6A2, and COL6A3). Collagen VI is a major structural component of the extracellular matrix surrounding muscle fibers, tendons, skin, and other connective tissues. When collagen VI is either reduced in quantity (quantitative defect) or structurally abnormal (qualitative defect), it leads to a range of clinical conditions collectively known as collagen VI-related myopathies. The most recognized conditions within this spectrum includ